Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Tratamiento de la bacteria SARM multirresistente

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20170413002
Publicado:
12/05/2017
Caducidad:
12/05/2018
Resumen:
Una universidad alemana ofrece derivados de alcaloides activos contra la bacteria SARM multirresistente. Estos derivados presentan un fuerte efecto bactericida, reprimiendo la formación de resistencia. La concentración mínima inhibitoria de los compuestos se encuentra en el rango submicromolar. Los compuestos son accesibles mediante síntesis one-pot. El andamio molecular puede modificarse fácilmente para desarrollar más derivados. La universidad busca socios en los sectores de biotecnología y farmacia interesados en incorporar el know-how en sus productos y establecer acuerdos de licencia y cooperación técnica para continuar con el desarrollo y estudios.

Details

Tittle:
Treatment of multi-resistant bacteria MRSA.
Summary:
A German university offers derivatives of alkaloids that are active against the multi-resistant bacteria MRSA. They show a strong bactericidal effect, thus repressing the formation of resistance. The inventors offer a license and a technical cooperation agreement.
Description:
Infection with methicillin-resistant Staphylococcus aureus (MRSA) is a major health problem in hospitals, long-term care facilities, and community medicine settings worldwide. There are new compounds in development for the treatment of MRSA. Unfortunately, there is a significant risk that new antibiotics targeting pathogen-specific proteins will exert the sort of selective pressure on the pathogen that ultimately leads to antibiotic resistance. Consequently, there is still a medical need for new antibiotics targeting MRSA.

A German university identified derivatives of the bis-indol-compounds hyrtinadine A and allocasine A as being active against MRSA. The minimum inhibitory concentration of compounds is in the sub-micromolar range. The strong bactericidal effect seems to suppress the formation of any resistances.

This offer addresses partners from the biotechnological and pharmaceutical sector who wish to integrate this know-how into their range of products. The university offers a license and technical cooperation agreement for further development and studies.
Advantages and Innovations:
The invented treatment addresses a yet unsolved problem: the medical need for new antibiotics. The identified derivatives show a strong bactericidal effect which seems to suppress the generation of any resistance. Beside the high potency an easy synthetical access is a key feature of the compounds. The compounds are accessible by a one-pot synthesis. The molecular scaffold may easily be modified in order to develop further derivatives.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European priority application has been filed.

Partner sought

Type and Role of Partner Sought:
The invented treatment is offered for license agreement as well as technical cooperation agreement. This offer addresses partners from the biotechnological and pharmaceutical sector who wish to integrate this know-how into their range of products. To use this invention it has to be further developed in form of preclinical and clinical studies.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos
06002003 Tecnología de enzimas
06001013 Tecnología médica / ingeniería biomédica